Human monoclonal antibodies against orexin receptor type 1
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Universite Paris Diderot—Paris 7, Institut Regional Du Cancer De Montpellier, Universite De Montpellier
InventorsAlain COUVINEAU, Thierry VOISIN, Pascal NICOLE, Bruno ROBERT, Pierre MARTINEAU, Myriam CHENTOUF
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or 70% identity with the above listed sequences.
Claims19
A human monoclonal antibody against OX1R comprising a heavy chain comprising i) a H-CDR1 having at least 50% identity with a H-CDR1 of C2, ii) a H-CDR2 having at least 50% identity with a H-CDR2 of C2 and iii) a H-CDR3 having at least 50% identity with a H-CDR3 of C2 of and/or a light chain comprising i) a L-CDR1 having at least 50% identity with a L-CDR1 of C2, ii) a L-CDR2 having at least 50% identity with a L-CDR2 of C2 and iii) a L-CDR3 having at least 50% identity with a L-CDR3 of C2 wherein
- the H-CDR1 of C2 is defined by a sequence ranging from an amino acid residue at position 31 to an amino acid residue at position 35 in SEQ ID NO:1,
- the H-CDR2 of C2 is defined by a sequence ranging from an amino acid residue at position 50 to an amino acid residue at position 66 in SEQ ID NO:1,
- the H-CDR3 of C2 is defined by a sequence ranging from an amino acid residue at position 99 to an amino acid residue at position 109 in SEQ ID NO:1,
- the L-CDR1 of C2 is defined by a sequence ranging from an amino acid residue at position 23 to an amino acid residue at position 36 in SEQ ID NO:2,
- the L-CDR2 of C2 is defined by a sequence ranging from an amino acid residue at position 52 to an amino acid residue at position 58 in SEQ ID NO:2, and,
- the L-CDR3 of C2 is defined by a sequence ranging from an amino acid residue at position 91 to an amino acid residue at position 100 in SEQ ID NO:2.
(canceled)
Dependencies are inferred from the claim text.